Gilead
NASDAQ:GILDPharmaFoster City, California, United States · Est. 1987 · 17,000 employees
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing medicines in virology, oncology, and inflammation.
25
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
36
Indications↗
Distinct diseases across all programs
723
Clinical Trials↗
All sponsored trials (all statuses)
59
Orange Book Patents
Across 7 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
25 drugs in development
Approved4
Phase 311
Phase 211
Phase 19
Preclinical5
By Therapeutic Area
top 6
Infectious Disease
1130%
Immunology
924%
Oncology
822%
Gastroenterology
38%
Metabolic & Endocrine
13%
Neurology
13%
R&D Momentum
80/100
Pipeline Velocity
42/100
Trial Completion Rate
77/100
Pipeline Concentration
21/100
Pipeline Freshness
63/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Active, not recruiting
A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
Jul 11, 2026
Recruiting
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Jul 11, 2026
Recruiting
A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
Jul 9, 2026
Active, not recruiting
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Jul 8, 2026
Active, not recruiting
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Jul 2, 2026
Recruiting
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Jul 2, 2026
Recruiting
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases
Jul 1, 2026
Terminated
A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Jul 1, 2026
Recruiting
Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)
Details
Company Info
Company Overview
$100.0B
Mkt Cap
$22.1B
Revenue
$5.3B
Cash
CEODaniel O'Day
Founded1987
Employees17,000
HQFoster City, California, United States
ExchangeNASDAQ:GILD
Websitegilead.com
LinkedInCompany Page
Therapeutic Focus
OncologyImmunologyInfectious DiseaseOtherHematologyGastroenterologyNephrologyMusculoskeletalNeurologyRare DiseaseRespiratoryOphthalmologyCardiovascularMetabolic & EndocrinePsychiatryDermatology
Recent SEC Filings
EX-99.1Feb 10, 2026
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology(3 drugs)
—
—
2
1
—
Gastroenterology(3 drugs)
Immunology(9 drugs)
—
4
2
3
—
Immunology(9 drugs)
Infectious Disease(11 drugs)
—
1
4
9
3
Infectious Disease(11 drugs)
Metabolic & Endocrine(1 drug)
—
1
—
—
—
Metabolic & Endocrine(1 drug)
Neurology(1 drug)
—
1
—
—
—
Neurology(1 drug)
Oncology(8 drugs)
4
3
5
1
—
Oncology(8 drugs)
Unknown / Other(4 drugs)
1
1
1
—
1
Unknown / Other(4 drugs)
Regulatory
Regulatory Timeline
20021 event
FDASep 20
Hepsera — HEPSERA
Application NDA021449 (NDA)
20031 event
FDAJul 2
Emtriva — EMTRIVA
Application NDA021500 (NDA)
20051 event
FDASep 28
Emtriva — EMTRIVA
Application NDA021896 (NDA)
20071 event
FDAJun 15
Letairis — LETAIRIS
Application NDA022081 (NDA)
20122 events
FDAJan 18
Viread — VIREAD
Application NDA021356 (NDA)
FDAJan 18
Viread — VIREAD
Application NDA022577 (NDA)
20142 events
FDASep 24
Vitekta — VITEKTA
Application NDA203093 (NDA)
FDAJul 23
Zydelig — ZYDELIG
Application NDA205858 (NDA)
20161 event
FDANov 10
Vemlidy — VEMLIDY
Application NDA208464 (NDA)
20192 events
FDAAug 28
Sovaldi — SOVALDI
Application NDA204671 (NDA)
FDAAug 28
Sovaldi — SOVALDI
Application NDA212480 (NDA)
20203 events
FDAOct 22
Veklury — VEKLURY
Application NDA214787 (NDA)
FDAApr 22
Trodelvy — TRODELVY
Application BLA761115 (BLA)
FDAApr 22
TRODELVY — TRODELVY
Application BLA761115 (BLA)
20222 events
FDADec 22
Sunlenca — SUNLENCA
Application NDA215974 (NDA)
FDADec 22
Sunlenca — SUNLENCA
Application NDA215973 (NDA)
20253 events
FDAJun 20
Tybost — TYBOST
Application NDA203094 (NDA)
FDAJun 18
Sunlenca — YEZTUGO
Application NDA220018 (NDA)
FDAJun 18
Sunlenca — YEZTUGO
Application NDA220020 (NDA)
20262 events
FDAMay 22
HEPCLUDEX — HEPCLUDEX
Application BLA761468 (BLA)
SECFeb 10
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Accession: 000-19731
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)